FLGC (Flora Growth) Debt-to-Revenue : 0.11 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Flora Growth Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Flora Growth's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.07 Mil. Flora Growth's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.23 Mil. Flora Growth's annualized Revenue for the quarter that ended in Sep. 2024 was $49.86 Mil. Flora Growth's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.11.

Flora Growth Debt-to-Revenue Historical Data

The historical data trend for Flora Growth's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flora Growth Debt-to-Revenue Chart

Flora Growth Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

6.12

0.15

0.11

0.05

Flora Growth Quarterly Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial													0.05	0.05	0.08	0.09	0.11

Competitive Comparison of Flora Growth's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Flora Growth's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Flora Growth's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Flora Growth's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Flora Growth's Debt-to-Revenue falls into.

Flora Growth Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Flora Growth's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.73	+	0.942)	/	76.071
	=	0.05

Flora Growth's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.067	+	2.233)	/	49.86
	=	0.11

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Flora Growth Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Flora Growth's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Flora Growth Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flora Growth Corp (NAS:FLGC) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

7301:Germany

Address

3406 South West 26th Terrace, Suite C-1, Fort Lauderdale, FL, USA, 33132

Website

https://www.floragrowth.com

Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.

Executives

Clifford Starke	director, officer: President	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Thomas Solomon	director	C/O FLORA GROWTH CORP., 365 BAY STREET; SUITE 800, TORONTO Z4 M5H 2V1
Kevin Taylor	director	C/O COOL HOLDINGS, INC., 2001 NW 84TH AVENUE, MIAMI FL 33122
Hussein Rakine	director, officer: Chief Executive Officer	5258 SW 183RD AVENUE, MIRAMAR FL 33029
Luis Merchan	director, officer: CEO & Chairman of the Board	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Roa Juan Carlos Gomez	director	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Beverley Richardson	director	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Elshad Garayev	officer: CFO	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Dany Vaiman	officer: Sr. VP Finance	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Matthew S. Cohen,	officer: General Counsel	C/O FLORA GROWTH CORP, 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Jessie Casner	officer: CMO	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Annabella Manalo Morgan	director	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Jason Warnock	officer: CCO	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Marc Mastronardi	director	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
John Timothy Leslie	director	C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312